NeuroPointDX
NeuroPointDX, a business unit of Stemina Biomarker Discovery, is bringing a precision medicine approach to the diagnosis and treatment of neurological disorders through the application of world-class metabolomics. The company’s current focus is autism spectrum disorder (ASD). NeuroPointDX has developed and is commercializing testing panels to aid in the early diagnosis of ASD through its CLIA-certified laboratory.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2016
- Employees:
- 11-100
Our Company
Stemina Biomarker Discovery markets its ASD diagnostics through its neurological disorders business unit, NeuroPointDX. Our first-generation test to assist with the diagnosis of autism spectrum disorder is the pinnacle of this work and has been our primary focus. We continue to look for ways to identify more children with ASD and to advise treatment that addresses their specific needs. Our work is also relevant to other neurological disorders that are notoriously difficult to diagnose and treat, including schizophrenia, depression, and anxiety.
Our Mission
We strive to improve the lives of children and families living with autism spectrum disorder and other neurological disorders by providing tools for earlier diagnosis and more precise treatment.
Leadership Team
NeuroPointDX’s leadership team combines experience, innovation, and teamwork to accomplish the company’s scientific and strategic goals. Their areas of expertise include metabolomics, bioinformatics, intellectual property, law, cell biology, drug discovery and development, personalized medicine, genetic testing, and business management. Members of the team have worked at the Wisconsin Alumni Research Foundation, Eli Lilly, EMD Millipore (Merck), Lineagen, and Alfigen, among others.
Earlier Diagnosis + More Precise Treatment = Better Outcomes
We improve the lives of children and families living with autism spectrum disorder (ASD) and other neurological disorders by providing tools for earlier diagnosis and more precise treatment. We continue to look for ways to identify more children with ASD and to advise treatment that addresses their specific needs. Read read our newest publication in Autism Research.The NPDX ASD blood test is a new diagnostic tool that may lead to an earlier diagnosis for children with ASD. Our test is validated by our National Institutes of Mental Health clinical study, the largest study to evaluate the metabolism of children with autism and published in the scientific journal, Biological Psychiatry.Talk to your healthcare Provider (pediatrician, family doctor) about requesting our test for your child. Print the NeuroPointDX brochure which summarizes our company and our autism test for your Provider. Your Provider will receive the test results and will recommend your options for treatments.
